NMRA-511
NMRA-511, also known as BTRX-323511 or NMRA-323511, is a vasopressin V 1A receptor antagonist which is under development for the treatment of agitation and anxiety disorders.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
NMRA-511, also known as BTRX-323511 or NMRA-323511, is a vasopressin V 1A receptor antagonist which is under development for the treatment of agitation and anxiety disorders. It has been found to reduce threat behaviors in marmosets. The drug was originated by BlackThorn Therapeutics and is under development by Neumora Therapeutics.
As of April 2026, it is in phase 1 clinical trials for agitation, whereas no decent development has been reported for anxiety disorders. The chemical structure of NMRA-511 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372174714 under CC BY-SA 4.0; modifications have been made.